Time: 5:00pm ~ 6:00pm, 16 Dec. 2020 (UTC+8 China Time)
Introduction: Packaging and delivery systems for vaccines are continually evolving as complexity increases, and the past six months especially have placed a spotlight on the readiness and requirements of pharma packaging companies to support the distribution and delivery of a potential COVID-19 vaccine. To extract as much value as possible from R&D, solutions must be developed with the end goal in mind. Selecting the most suitable primary packaging options for drug products is one of the most crucial considerations in the drug development process and getting this wrong can result in additional costs and challenges later down the line. This webinar will examine packaging solutions which de-risk the drug development process for vaccines, manage costs and facilitate speed to market.
Key discussion points:
· Market outlook for vaccine development and packaging solutions
· COVID-19 vaccine development in focus
· Road mapping the selection of primary containers - formulation considerations and filling technologies
· How can cost, value and scale be balanced?
Yasemin is a Consultant in the European Thought Leadership team based in IQVIA’s London office. Her primary areas of focus are; trends in innovative launches, drug delivery and formulations as well as the oncology market with an emphasis on commercial trends. She has presented and moderated panels on these subjects in a variety of conferences. Yasemin holds a Masters in Cancer Research and a Bachelor of Science degree in Biomedical Sciences both from Newcastle University. Prior to her role in Thought Leadership, Yasemin was part of the Real-World Insights – Global Oncology team where she worked on the co-ordination and set-up of reports focusing on various cancers.
Kris is a vaccines and pharmaceutical consultant for organizations such as UNIDO, GIZ and WHO as well as global and LMIC vaccine/pharma companies.
His work focuses on enabling mid-sized biotech and pharma firms to accelerate their growth through a mix of current facility operations optimization, planning for new facilities and helping them to secure strategic production partnerships. He is the author of three reports on vaccine manufacturing as part of an ongoing project conducted by UNIDO, WHO and AVMI.
In his former role at Merck & Co. Inc (MSD), Kris evaluated and implemented local vaccine and pharma technology transfer deals in LMIC countries to facilitate MSD’s global expansion plans. Prior to this, he was part of MSD’s team responsible for designing, constructing, starting up and optimizing production facilities around the world. In this role he worked on new vaccine facility projects ranging in size from $15M to $300M. During his career he has worked extensively in the US, Latin America, Africa and Europe.
Daniel Martinez is Product Manager for Syringes, Components and SG Lab at Stevanato Group since 2017. In his role he is responsible for the development and go-to-market strategy of syringes and add-on components as well as analytical services. He has experience in different aspects and functions such as production, technical liaison, quality, project management and sales.
He holds a bachelor’s degree in Mechatronics Engineering from the Instituto Tecnológico y de Estudios Superiores de Monterrey. Prior to joining Stevanato Group, Mr Martinez has been covering commercial and operational roles in international companies dedicated to primary packaging.